(American College of Chest Physicians) Adherence to inhaled and oral therapies for cystic fibrosis patients is discouragingly low, ranging 31-35 percent for inhaled antibiotics. Programs to enhance adherence have had mixed success; a new pilot study from Ventura County Medical Center in Ventura, California, shows remarkable improvement in adherence using Bluetooth technology.
A trial to test the safety and effectiveness of a therapy that replaces a faulty gene in the lungs of patients with cystic fibrosis has shown encouraging results.
A mouse study of an improved gene therapy suggests it shows promise as a treatment for cystic fibrosis, but there is still a long way to go before it can be tested in humans.
At the 31st European Cystic Fibrosis Society (ECFS) Annual Meeting in Prague, Czech Republic, researchers presented interim results from the first clinical trial of the investigational oral agent VX-770 in cystic fibrosis patients.
A new study found that the combination of inhaled dry powder mannitol with standard therapy for cystic fibrosis resulted in maintained improvement in lung function for 12 months. In addition to being effective and safe, the easy adm...